| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anita Slomsk. Cannabinoid Agonist Reduces Cannabis Use. JAMA. vol 322. issue 12. 2019-10-04. PMID:31550029. |
cannabinoid agonist reduces cannabis use. |
2019-10-04 |
2023-08-13 |
Not clear |
| Linda K Friedman, Joann P Wongvravi. Anticonvulsant and Neuroprotective Effects of Cannabidiol During the Juvenile Period. Journal of neuropathology and experimental neurology. vol 77. issue 10. 2019-10-03. PMID:30169677. |
anticonvulsant effects of cannabidiol (cbd), a nonpsychoactive cannabinoid, have not been investigated in the juvenile brain. |
2019-10-03 |
2023-08-13 |
Not clear |
| Catherine J Lucas, Peter Galettis, Shuzhen Song, Nadia Solowij, Stephanie E Reuter, Jennifer Schneider, Jennifer H Marti. Cannabinoid Disposition After Human Intraperitoneal Use: AnInsight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer. Clinical therapeutics. vol 40. issue 9. 2019-09-30. PMID:29317112. |
the pharmacokinetic properties of cannabis administered by traditional routes has been described but to date, there is no literature on the pharmacokinetic properties of an intraperitoneal cannabinoid emulsion. |
2019-09-30 |
2023-08-13 |
human |
| Nick Jikomes, Michael Zooro. The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products. Scientific reports. vol 8. issue 1. 2019-09-30. PMID:29540728. |
the cannabinoid content of legal cannabis in washington state varies systematically across testing facilities and popular consumer products. |
2019-09-30 |
2023-08-13 |
Not clear |
| Nick Jikomes, Michael Zooro. The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products. Scientific reports. vol 8. issue 1. 2019-09-30. PMID:29540728. |
to investigate these concerns, we analyzed a publicly available seed-to-sale traceability dataset from washington state containing measurements of the cannabinoid content of legal cannabis products from state-certified laboratories. |
2019-09-30 |
2023-08-13 |
Not clear |
| Joao P De Aquino, Mohamed Sherif, Rajiv Radhakrishnan, John D Cahill, Mohini Ranganathan, Deepak C D'Souz. The Psychiatric Consequences of Cannabinoids. Clinical therapeutics. vol 40. issue 9. 2019-09-30. PMID:29678279. |
with rising rates of cannabis use in the general population and an increasing number of us states legalizing both recreational and medical cannabis use, it is important to be informed about the adverse consequences of cannabinoids. |
2019-09-30 |
2023-08-13 |
Not clear |
| Peter E W. Cannabinoid hyperemesis syndrome: caution with urine drug screens for marijuana. BMJ (Clinical research ed.). vol 366. 2019-09-26. PMID:31548253. |
cannabinoid hyperemesis syndrome: caution with urine drug screens for marijuana. |
2019-09-26 |
2023-08-13 |
Not clear |
| Francisco Navarrete, Auxiliadora Aracil-Fernández, Jorge Manzanare. Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal. British journal of pharmacology. vol 175. issue 13. 2019-09-24. PMID:29624642. |
cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal. |
2019-09-24 |
2023-08-13 |
Not clear |
| Hollis C Karoly, L Cinnamon Bidwell, Raeghan L Mueller, Kent E Hutchiso. Investigating the Relationships Between Alcohol Consumption, Cannabis Use, and Circulating Cytokines: A Preliminary Analysis. Alcoholism, clinical and experimental research. vol 42. issue 3. 2019-09-17. PMID:29286537. |
conversely, cannabis is associated with decreased inflammatory signaling, and animal studies suggest that cannabinoids may impact alcohol-induced inflammation. |
2019-09-17 |
2023-08-13 |
human |
| Jessica Rice, Michelle Camero. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. Current neurology and neuroscience reports. vol 18. issue 8. 2019-09-17. PMID:29923025. |
cannabis and cannabinoids have been used medically and recreationally for thousands of years and recently there has been a growing body of research in this area. |
2019-09-17 |
2023-08-13 |
Not clear |
| Jessica Rice, Michelle Camero. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. Current neurology and neuroscience reports. vol 18. issue 8. 2019-09-17. PMID:29923025. |
with increased access now that medical marijuana is available in many jurisdictions, patients and providers want to know more about the evidence for benefits and risks of cannabinoid use. |
2019-09-17 |
2023-08-13 |
Not clear |
| Tim Rasche, Dorian Emmert, Lukas Radbruch, Rupert Conrad, Martin Mück. [Cannabis and cannabinoids in palliative care]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. vol 62. issue 7. 2019-09-17. PMID:31161228. |
[cannabis and cannabinoids in palliative care]. |
2019-09-17 |
2023-08-13 |
Not clear |
| Tim Rasche, Dorian Emmert, Lukas Radbruch, Rupert Conrad, Martin Mück. [Cannabis and cannabinoids in palliative care]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. vol 62. issue 7. 2019-09-17. PMID:31161228. |
cannabis and cannabinoids are discussed as a potential treatment for a broad spectrum of diseases and symptoms. |
2019-09-17 |
2023-08-13 |
Not clear |
| Tim Rasche, Dorian Emmert, Lukas Radbruch, Rupert Conrad, Martin Mück. [Cannabis and cannabinoids in palliative care]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. vol 62. issue 7. 2019-09-17. PMID:31161228. |
this article presents current evidence for the use of cannabis and cannabinoids in palliative care and delivers background information. |
2019-09-17 |
2023-08-13 |
Not clear |
| Tim Rasche, Dorian Emmert, Lukas Radbruch, Rupert Conrad, Martin Mück. [Cannabis and cannabinoids in palliative care]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. vol 62. issue 7. 2019-09-17. PMID:31161228. |
the authors focused on a systematic review and meta-analysis of cannabinoids in palliative care by mücke et al.overall, there is no high-quality evidence for the use of cannabis and cannabinoids in palliative care. |
2019-09-17 |
2023-08-13 |
Not clear |
| Tim Rasche, Dorian Emmert, Lukas Radbruch, Rupert Conrad, Martin Mück. [Cannabis and cannabinoids in palliative care]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. vol 62. issue 7. 2019-09-17. PMID:31161228. |
cannabinoids may be considered as a therapeutic attempt in the treatment of cancer pain and weight gain in patients with hiv as well as other symptoms (such as nausea and loss of appetite) if established treatments fail.further studies involving more patients are needed to evaluate the therapeutic potential of cannabis and cannabinoids. |
2019-09-17 |
2023-08-13 |
Not clear |
| David M Elliott, Narendra Singh, Mitzi Nagarkatti, Prakash S Nagarkatt. Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells. Frontiers in immunology. vol 9. 2019-09-16. PMID:30123217. |
while the use of marijuana cannabinoids for ms has recently been approved in some countries, the precise mechanism of action leading to attenuate neuroinflammation is not clear. |
2019-09-16 |
2023-08-13 |
mouse |
| David M Elliott, Narendra Singh, Mitzi Nagarkatti, Prakash S Nagarkatt. Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells. Frontiers in immunology. vol 9. 2019-09-16. PMID:30123217. |
we used experimental autoimmune encephalomyelitis (eae), a murine model of ms, to explore the anti-inflammatory properties of cannabidiol (cbd), a non-psychoactive cannabinoid. |
2019-09-16 |
2023-08-13 |
mouse |
| Patrick Makary, Jayesh R Parmar, Natalie Mims, Nile M Khanfar, Robert A Freema. Patient Counseling Guidelines for the Use of Cannabis for the Treatment of Chemotherapy-Induced Nausea/Vomiting and Chronic Pain. Journal of pain & palliative care pharmacotherapy. vol 32. issue 4. 2019-09-16. PMID:31070496. |
a literature search was performed using medline/pubmed resources and google scholar between july 2015 and august 2018 using broad search terms, e.g., cannabinoids adverse effects, cannabis, natural cannabinoids, and tetrahydrocannabinol. |
2019-09-16 |
2023-08-13 |
Not clear |
| Gabriela Seabra, Ana Caroline B Falvella, Paul C Guest, Daniel Martins-de-Souza, Valéria de Almeid. Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains. Proteomics. vol 18. issue 18. 2019-09-12. PMID:30070429. |
interest in the modulation of endocannabinoid signaling has increased since the discovery of receptors for compounds of cannabis sativa. |
2019-09-12 |
2023-08-13 |
Not clear |